SCHEMBL3274521

SCHEMBL3274521

CCOC(=O)CNC(=O)c1ccc(S(=O)(=O)Nc2ccccc2Oc2ccc(F)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1H O95180 3/20 0.53
CACNA1B Q00975 3/20 0.53
TDP1 Q9NUW8 4/20 0.52
MRGPRX1 Q96LB2 1/20 0.50
HTT P42858 4/20 0.48
NPC1 O15118 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
RAB9A P51151 1/20 0.48
KMT2A Q03164 2/20 0.47
BCL2L1 Q07817 1/20 0.47
MCL1 Q07820 1/20 0.47
LMNA P02545 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TP53 P04637 1/20 0.46
HPGD P15428 1/20 0.46
UBE2N P61088 1/20 0.45
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3045528 0.93 TDP1 (0.54) CACNA1HCACNA1BTDP1HTTNPC1
SCHEMBL3274410 0.93 CACNA1H (0.58) CACNA1HCACNA1BTDP1HTTNPC1
SCHEMBL3273893 0.92 TDP1 (0.49) CACNA1HCACNA1BTDP1MRGPRX1HTT
SCHEMBL3275031 0.91 MRGPRX1 (0.49) MRGPRX1NPC1SMN1; SMN2RAB9AKMT2A
SCHEMBL3273823 0.87 CACNA1H (0.55) CACNA1HCACNA1BTDP1MRGPRX1KMT2A
SCHEMBL3052348 0.86 CCR2 (0.45) MRGPRX1NPC1SMN1; SMN2RAB9AKMT2A
SCHEMBL3052650 0.86 CCR2 (0.48) KMT2ALMNAKDM4EALDH1A1HPGD
SCHEMBL3053653 0.81 PTGDR2 (0.49)
SCHEMBL3281479 0.80 CACNA1H (0.59) CACNA1HCACNA1BTDP1L3MBTL1MAPT
SCHEMBL15104080 0.80 GAA (0.51) CACNA1HCACNA1BMRGPRX1NPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2076491-B1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-07-17 EP disclosed
US-8481527-B2 Benzamide derivatives as bradykinin antagonists RICHTER GEDEON NYRT. (HU) 2013-07-09 US disclosed
US-20100087423-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-04-08 US disclosed
EP-2076491-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS Richter Gedeon NYRT (HU) 2009-07-08 EP disclosed
WO-2008068540-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087423-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, HRH1 CACNA1H 997/4885CACNA1B 915/4885TDP1 4124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.